《半日总结》恒指升23点 科网及药股扬 地产股走弱
中国新型冠状病毒疫情扩散，中国股市复市显着受压，港股上周累计跌逾千六点後表现反覆。恒指低开123点後，曾跌167点见26,145点，其後曾倒升近200点，随後再度倒跌。半日升23点或0.1%，报26,336点；国指升49点或0.5%，报10,289点。大市半日成交总额782.81亿元，沪、深港通南下交易半日净流入金额分别为11.95亿及5.98亿元人民币。
阿里巴巴(09988.HK)升2%报204.4元，腾讯(00700.HK)升1.7%报379.4元，友邦(01299.HK)升0.4%报78.05元，汇控(00005.HK)跌1.1%报56.25元，港交所(00388.HK)及中移动(00941.HK)各跌0.3%及0.2%。内银股建行(00939.HK)及工行(01398.HK)各升1.3%及1.7%，中国平安(02318.HK)跌1.1%，美团点评(03690.HK)升1.1%重上100元，小米(01810.HK)升3.8%。
其他科网股个别发展，金山软件(03888.HK)、中软(00354.HK)、IGG(00799.HK)、美图(01357.HK)各升2.3%至2.9%，金蝶(00268.HK)及网龙(00777.HK)各升4.5%及5.7%。阅文(00772.HK)、同程艺龙(00780.HK)及阿里健康(00241.HK)各跌2.9%至4%。半导体股中芯(00981.HK)及华虹半导体(01347.HK)各升3.2%及2.4%，电讯设备股中兴(00763.HK)及京信通信(02342.HK)各升2.1%及2.5%。手机相关股方面，舜宇(02382.HK)升1.3%，比亚迪电子(00285.HK)、鸿腾(06088.HK)及富智康(02038.HK)各跌2%至3.3%。
医药股普遍上升，石药(01093.HK)及中生制药(01177.HK)各升3.8%及4.6%，中国中药(00570.HK)、信达生物(01801.HK)及药明康德(02359.HK)各升3%至3.9%，华润医药(03320.HK)升5.1%。中小型医药股炒作持续。福森药业(01652.HK)急升53%，歌礼药业(01672.HK)升33%。歌礼制药指旗下产品被使用作新型肺炎临床试验。
内需股方面，安踏(02020.HK)跌2.3%报66.6元，李宁(02331.HK)跌2.8%，呷哺呷哺(00520.HK)及阿里影业(01060.HK)各跌7.3%及5.4%，维达(03331.HK)、恒安(01044.HK)及康师傅(00322.HK)各升1.6%至2%。
本地地产股跑输大市，领展(00823.HK)、九仓置业(01997.HK)及长实集团(01113.HK)各跌2%、1.7%及1.6%，太古地产(01972.HK)跌2.1%，港铁(00066.HK)亦跌1.7%。濠赌股银娱(00027.HK)及金沙中国(01928.HK)各升1.2%及1.5%。
黄金股急跌，招金(01818.HK)及山东黄金(01787.HK)各跌5.4%，中国黄金国际(02099.HK)跌6.3%。资源股受压，中国铝业(02600.HK)及俄铝(00486.HK)各跌3%及4.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
